TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06701435

Intervention type: DEVICE
Intervention: Cold Compression
Description: Cold compression was applied to the athletes with the Game Ready (Game Ready; Global, UK) device. The Game Ready (GR) device applies cooling to the tissue by continuous circulation of ice water with intermittent pneumatic compression. The GR consists of a sleeve that surrounds the affected tissue, a tank containing the ice water and a hose connecting the two. There are chambers inside the sleeve and the air pumped through these chambers and the broken ice pieces and water surround the tissue. The pressure settings are no compression (0 mmHg), low compression (5 to 15 mmHg), medium compression (5 to 50 mmHg) and high compression (5 to 75 mmHg). The ice water passes through the sleeve in 3-minute inflation and deflation cycles. The temperature of the water inside the device can be adjusted by adding ice and water. The temperature to be applied to the tissue is set with the screen on the device.

Intervention type: DEVICE
Intervention: Cold Compression
Description: Cold compression was applied to the athletes with the Game Ready (Game Ready; Global, UK) device. The Game Ready (GR) device applies cooling to the tissue by continuous circulation of ice water with intermittent pneumatic compression. The GR consists of a sleeve that surrounds the affected tissue, a tank containing the ice water and a hose connecting the two. There are chambers inside the sleeve and the air pumped through these chambers and the broken ice pieces and water surround the tissue. The pressure settings are no compression (0 mmHg), low compression (5 to 15 mmHg), medium compression (5 to 50 mmHg) and high compression (5 to 75 mmHg). The ice water passes through the sleeve in 3-minute inflation and deflation cycles. The temperature of the water inside the device can be adjusted by adding ice and water. The temperature to be applied to the tissue is set with the screen on the device.
Study: NCT06721026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous intravenous stable isotope amino acid tracer infusion
Description: During the single 12 h trial day, a primed continuous stable isotope infusion will run in order to assess muscle protein synthesis in the basal (4 h) and post-prandial (8 h) state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Description: In order to assess muscle protein synthesis rates during continuous elevated plasma amino acid availability, the amino acid infusion solution Vamin®14 EF will be used. Vamin® 14EF contains 85g amino acids per liter and will be administered in the post-prandial period for 8 hours to ensure a constant rate of amino acid infusion over the full assessment period of the primary outcome measure.
Study: NCT05004987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Oxalate
Description: The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo will mimic that of ESC.
Study: NCT06717685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil Injection
Description: Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate.
Study: NCT06733246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration 0
Description: Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.
Study: NCT06732388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT05353374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fusidate 2 % Topical Ointment
Description: Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum ointment
Description: Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
Study: NCT06544525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The intervention will be physical therapy standard of care.
Study: NCT05368142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nocardia rubra Cell Wall Skeleton
Description: Nocardia rubra cell wall skeleton for external application
Study: NCT06732388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05368142

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silver ions dressing
Description: Silver ions dressing for external application
Study: NCT06732388

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy
Study: NCT04984109

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham PENG block
Description: The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real PENG block
Description: The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
Study: NCT06732388

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Undergo radiofrequency ablation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Undergo radiofrequency ablation
Study: NCT05670379

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exenatide Implant
Description: Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bydureon BCise (exenatide extended release)
Description: glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.0 mg/mL
Description: glucagon-like peptide-1 (GLP-1) receptor agonist
Study: NCT06454032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness walking
Description: Fitness walking for 12 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Maintained lifestyle
Description: Maintained their normal lifestyle, without exercise intervention.
Study: NCT06182306

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Patients undergo a biopsy from a lesion, and give 40ml of blood
Study: NCT04896398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: In the study group, a total of 5 sessions of focused ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the affected wrist within 2 weeks.
Study: NCT06406647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retrocalvicular block
Description: retrocalvicular block in upper limb orthopedic Surgey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retrocalvicular block
Description: retrocalvicular block in upper limb orthopedic Surgey
Study: NCT06042283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training-Silver
Description: The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period.
Study: NCT06347497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT06279546

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of structures
Description: Pre-recorded videos, cropped according to the different windows (mediastinal, gastric, duodenal) will be analyzed by the AIWorks-EUS model and endoscopists on different times for recognition of the different normal anatomical structures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of structures
Description: Pre-recorded videos, cropped according to the different windows (mediastinal, gastric, duodenal) will be analyzed by the AIWorks-EUS model and endoscopists on different times for recognition of the different normal anatomical structures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of structures
Description: Pre-recorded videos, cropped according to the different windows (mediastinal, gastric, duodenal) will be analyzed by the AIWorks-EUS model and endoscopists on different times for recognition of the different normal anatomical structures.
Study: NCT06065917

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of the total small bowel length using CT scan and MRI with 3D reconstruction and AI tool
Description: The intervention consists in performing CT and MR imaging with small bowel length measurement before bariatric/metabolic surgery in obese patients. Then, during surgery the patients will undergo laparoscopic stretched small bowel measurement as the reference gold standard method to measure the small bowel length. The imaging of the training cohort will be used to trained an AI to set up an automatic method of small bowel length measurement via the analysis of CT and MRI imaging.
Study: NCT04720924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided Real-time Automatic Quality-control System
Description: EGD automatic quality-control system(AQCS),developed based on deep convolutional neural network (DCNN) models,could facilitate real-time detection of upper gastrointestinal lesions, assess inspection completeness and mucosal visibility, and calculate time of EGD procedure.
Study: NCT05540925

Intervention type: PROCEDURE
Intervention: Liver resection
Description: All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups.

Intervention type: PROCEDURE
Intervention: Liver resection
Description: All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups.
Study: NCT05347264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gun massager
Description: 15 to 20 minutes along with hot pack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transverse friction massage
Description: 15 to 20 minutes along with hot pack.
Study: NCT05087082

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Hospital at Home - Home admission of epidemic patients
Description: Admitting COVID-19 patients at home
Study: NCT04167033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy:effect on ventricular repolarization
Description: Hormone replacement therapy and QTc measurement

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG
Description: QTc measurement
Study: NCT06347497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05427565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine
Description: The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental time
Description: The investigators will ask participant to attend the experiment in the morning or afternoon
Study: NCT05306041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: daily application of 9 mg (may be decreased to 6 mg and to 3 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHESGO
Description: fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)

Intervention type: DRUG
Group type: OTHER
Intervention: PHESGO
Description: fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men

Intervention type: DRUG
Group type: OTHER
Intervention: Endocrine therapy
Description: Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
Study: NCT03468556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP-610
Description: Subjects will take 2 tablets once a day orally for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects will take 2 tablets once a day orally for 12 weeks
Study: NCT06363370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human interferon α1b Inhalation Solution
Description: Participants will receive Human interferon α1b Inhalation Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human interferon α1b Inhalation Solution
Description: Participants will receive Human interferon α1b Inhalation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation Solution Placebo
Description: Participants will receive Inhalation Solution Placebo
Study: NCT04869774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: How2Trak mobile application
Description: Patients will undergo virtual monitoring of their incision and symptoms using the How2Trak application(app). Using the app, patients will be asked to answer a series of questions and photograph their surgical incision on post-operative day 3, 5, 7, 10, 20, and 30. Patient responses and photographs entered into the app will be reviewed within 72 hours by a trained Nurse Specialized in Wound, Ostomy and Continence. If a concern is identified the nurse will contact the patient to arrange a virtual visit using the how2trak app or notify the surgeon team (including colorectal surgeons and physician residents) in accordance with clinical discretion.
Study: NCT06455293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring
Study: NCT06068985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHESGO
Description: Subcutaneous formulation with pertuzumab and trastuzumab.
Study: NCT05918601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-risk behaviors
Description: Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Theory of planned behavior, Self-determination theory
Description: The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theory of planned behavior, Self-determination theory
Description: The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assist them to adhere to their schedule of quitting drugs throughout the study period
Description: The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assist them to adhere to their schedule of quitting drugs throughout the study period
Description: The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period
Description: The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: (AWARD) model
Description: Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (AWARD) model
Description: Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Receive four independent 1-minute videos
Description: The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive four independent 1-minute videos
Description: The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
Study: NCT06128928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDES
Description: Training on motivational interviewing (MI) led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Brief CHW-led training about the safety and efficacy of the COVID-19 vaccine. Participants will have the opportunity to ask clarifying questions from the CHWs during the training.